Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$68.49
$68.47
$21.65
$73.02
$4.62B0.452.07 million shs74 shs
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.87
$68.98
$131.98
$14.05B0.691.53 million shsN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$113.76
-0.7%
$108.41
$85.18
$129.90
$2.19B0.84118,079 shs98,761 shs
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
$2.81
-3.1%
$4.50
$2.19
$26.98
$300.08M0.672.22 million shs2.45 million shs
Xencor, Inc. stock logo
XNCR
Xencor
$7.94
-5.7%
$8.66
$7.16
$27.24
$565.09M0.85680,460 shs564,037 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00%0.00%0.00%0.00%0.00%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%0.00%+89.58%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
0.00%+0.21%+7.92%+15.06%+35.58%
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.00%+14.47%-5.67%-44.20%-85.49%
Xencor, Inc. stock logo
XNCR
Xencor
0.00%+3.26%-12.90%+0.42%-53.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.9328 of 5 stars
1.10.00.04.50.01.70.6
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
4.8008 of 5 stars
3.53.00.04.42.73.31.9
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
4.8147 of 5 stars
4.22.00.04.71.15.01.3
Xencor, Inc. stock logo
XNCR
Xencor
3.9886 of 5 stars
3.42.00.03.91.90.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
0.00
N/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$146.1428.47% Upside
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
2.41
Hold$18.60561.92% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00252.64% Upside

Current Analyst Ratings Breakdown

Latest ITCI, XNCR, LGND, GBT, and RCKT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $5.00
6/3/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$34.00 ➝ $11.00
5/30/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ In-Line$5.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $9.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $8.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$51.00 ➝ $19.00
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell
5/28/2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$37.00 ➝ $8.00
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
$194.75M23.73N/AN/A$3.05 per share22.46
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M13.13$1.60 per share71.31$43.95 per share2.59
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/A$5.08 per shareN/A
Xencor, Inc. stock logo
XNCR
Xencor
$110.49M5.11N/AN/A$9.63 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$7.12N/A30.66N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$258.75M-$2.63N/AN/AN/AN/A-64.92%-56.13%8/4/2025 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)

Latest ITCI, XNCR, LGND, GBT, and RCKT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q2 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.57N/AN/AN/A$4.36 millionN/A
8/4/2025Q2 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.78N/AN/AN/A$22.59 millionN/A
5/13/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.58-$0.56+$0.02N/AN/AN/A
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
5/5/2025Q1 2025
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
-$0.59-$0.56+$0.03-$0.56$0.80 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
4.92
6.88
6.17
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.27
5.02
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
0.05
9.19
9.19
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89
CompanyEmployeesShares OutstandingFree FloatOptionable
Global Blood Therapeutics, Inc. stock logo
GBT
Global Blood Therapeutics
45767.48 million64.17 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.94 millionOptionable
Rocket Pharmaceuticals, Inc. stock logo
RCKT
Rocket Pharmaceuticals
240106.79 million80.35 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.45 millionOptionable

Recent News About These Companies

Xencor Reports First Quarter 2025 Financial Results
Xencor initiated with an Outperform at William Blair

New MarketBeat Followers Over Time

Media Sentiment Over Time

Global Blood Therapeutics stock logo

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)
As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$113.76 -0.82 (-0.72%)
As of 04:00 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Rocket Pharmaceuticals stock logo

Rocket Pharmaceuticals NASDAQ:RCKT

$2.81 -0.09 (-3.10%)
Closing price 04:00 PM Eastern
Extended Trading
$2.83 +0.02 (+0.71%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Xencor stock logo

Xencor NASDAQ:XNCR

$7.94 -0.48 (-5.70%)
As of 04:00 PM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.